Business Context and Reporting Period
Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended December 31, 1999 (First Quarter of Fiscal 2000)
Business Overview: BD operates through three principal segments: BD Medical Systems, BD Biosciences, and BD Preanalytical Solutions. The company manufactures medical devices, diagnostic products, and preanalytical solutions.
Key Financial Metrics
| Metric | Q1 1999 (Current) | Q1 1998 (Prior Year) |
|---|---|---|
| Revenues | $859.2 million | $769.0 million |
| Net Income | $75.3 million | $76.2 million |
| Diluted EPS | $0.29 | $0.29 |
| Operating Income | $121.6 million | $110.8 million |
| Operating Margin | 14.2% | 14.4% |
| Gross Profit Margin | 47.6% | 49.8% |
| Net Cash from Operations | $121.2 million | $86.9 million |
| Total Debt | $1.56 billion | N/A (Balance Sheet data only) |
| Cash and Equivalents | $70.9 million | $59.9 million (Sep 30, 1999) |
Note: Total debt is calculated as Short-term debt ($611.3M) + Long-term debt ($953.4M) as of Dec 31, 1999.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 12% year-over-year. Growth was driven by recent acquisitions (adding ~$26M) and strong international sales of core products. However, a strengthened U.S. dollar reduced revenues by an estimated $11 million.
- Profitability: While operating income rose 10%, Net Income remained flat compared to the prior year. This was due to a higher effective tax rate (26% vs. 19% in the prior year, which included a favorable $7M tax judgment in Brazil) and increased interest expense.
- Margins: Gross profit margin declined to 47.6% from 49.8%, attributed to an unfavorable sales mix in emerging markets and higher costs associated with scaling production of advanced protection devices. Selling and administrative expenses improved to 27.2% of revenue from 29%.
- Cash Flow: Operating cash flow increased significantly to $121.2 million from $86.9 million, reflecting tighter cash management and lower inventory build-up compared to the prior year.
Guidance, Outlook, and Risks
- Outlook: Management expects gross profit margins to improve in the remaining quarters of fiscal 2000. Capital spending for fiscal 2000 is projected to be approximately $350 million, focusing on manufacturing capacity for advanced protection devices.
- Dividends: The Board increased the quarterly dividend to $0.0925 per share from $0.085.
- Year 2000 Compliance: The company believes it has completed all necessary modifications to avoid Y2K disruptions. Approximately $17 million in costs have been incurred. Management cannot assure that third-party failures will not impact operations.
- Legal Contingencies: BD is a defendant in approximately 335 product liability lawsuits regarding natural rubber latex and 11 class action suits regarding needle-stick injuries. Management does not expect these to have a material impact on financial results, though a Texas court conditionally granted class certification in one needle-stick case (appealed).
- Accounting Changes: The company is evaluating the impact of SFAS No. 133 regarding derivative instruments, with adoption expected by the first quarter of fiscal 2001.
Investor Verification Checklist
- Margin Recovery: Verify if gross profit margins improve in subsequent quarters as management predicts, given the current decline to 47.6%.
- Y2K Impact: Monitor for any operational disruptions or supply chain issues arising from third-party Y2K failures, despite BD's internal compliance.
- Legal Exposure: Track the status of the Usrey v. Becton, Dickinson class action appeal in Texas and the potential for similar certifications in other jurisdictions.
- Debt Levels: Review the debt-to-capital ratio (46.3% at period end) and the company's ability to service debt given the increased interest expense.
- Acquisition Integration: Assess the long-term contribution of recent acquisitions to the Biosciences and Medical Systems segments beyond the initial revenue boost.